# US 2021/0061876 A1 · T cell receptors for tumor specific proteasome splice variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061876 A1
- Document ID: US20210061876A1
- Status: Published application
- Kind: A1
- Application number: 16/958,604
- Filed: 2019-01-02
- Published: 2021-03-04
- Earliest claimed: 2017-12-29
- Assignees: Max-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft; Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts; Imperial College Innovations Limited; Charite-Universitatsmedizin Berlin
- Applicants: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft; Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts; Imperial College Innovations Limited; Charité - Universitätsmedizin Berlin
- Inventors: Thomas BLANKENSTEIN; Gerald WILLIMSKY; Juliane LIEPE; Peter Michael KLOETZEL; Michele MISHTO; Christin BEIER
- Web page: https://patentgrep.com/patent/US20210061876A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4253: {GTPases, e.g. Ras or Rho}
- C07K 14/82: Translation products from oncogenes
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C07K 16/32: against translation products of oncogenes
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention pertains to antigen recognizing constructs against tumor specific proteasome splicing variants. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for tumor cells carrying antigenic epitopes generated by proteasome peptide splicing of tumor specific antigens. The TCRs of the invention, and antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of proliferative diseases, preferably for the treatment of cancer. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

An antigen recognizing construct, comprising at least one complementary determining region which specifically recognizes a mutated Ras antigen such as a mutated RasG12, preferably wherein the spliced peptide variant comprises a sequence according to SEQ ID NO: 76 to 78, or 163.

### Claim 30 (depends on 29)

The antigen recognizing construct according to claim 29, comprising at least one complementary determining region (CDR) 3 having at least 80% sequence identity to an amino acid sequence selected from SEQ ID NOs. 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, and 71, or a CDR3 shown in table 1a in each case independently, optionally with not more than three or two, preferably no more than one, amino acid substitution(s), insertion(s) or deletion(s) compared to these sequences.

### Claim 31 (depends on 29)

The antigen recognizing construct according to claim 29, wherein the antigen recognizing construct is an α/β-TCR, or fragment or derivative thereof, or the construct is a γ/δ-TCR, or a fragment or derivative thereof.

### Claim 32 (depends on 29)

The antigen recognizing construct according to claim 29, comprising a TCR α or γ chain; and/or a TCR β or δ chain; wherein the TCR α or γ chain comprises a CDR3 having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos. 3, 11, 19, 27, 35, 43, 51, 59, and 67 or an alpha chain CDR3 shown in table 1a, and/or wherein the TCR β or δ chain comprises a CDR3 having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos. 7, 15, 23, 31, 39, 47, 55, 63, and 71 or a beta chain CDR3 shown in table 1a; in each case independently, optionally with not more than three or two, preferably no more than one, amino acid substitution(s), insertion(s) or deletion(s) compared to these sequences.

### Claim 33 (depends on 29)

The antigen recognizing construct according to claim 29, comprising a TCR variable chain region having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos. 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72 or a variable domain sequence shown in table 1a, in each case independently, optionally with not more than three or two, preferably no more than one, amino acid substitution(s), insertion(s) or deletion(s) compared to these sequences.

### Claim 34 (depends on 29)

The antigen recognizing construct according to claim 29, wherein the construct is fully or partially humanized, chimerized and/or murinized.

### Claim 35 (depends on 29)

The antigen recognizing construct according to claim 29, wherein the construct is a TCR, or a fragment thereof, composed of at least one TCR α and one TCR β chain sequence, wherein said TCR α chain sequence and said TCR β chain sequence is selected from the following combinations:
Alpha Chain CDR1, CDR2, CDR3
Beta Chain CDR1, CDR2, CDR3
(SEQ ID NO)
(SEQ ID NO)
1
2
3
5
6
7
9
10
11
13
14
15
17
18
19
21
22
23
25
26
27
29
30
31
33
34
35
37
38
39
41
42
43
45
46
47
49
50
51
53
54
55
57
58
59
61
62
63
65
66
67
69
70
71
1
2
3
79
80
81
9
10
11
83
84
85
9
10
11
87
88
89
91
92
93
103
104
105
95
96
97
103
104
105
99
100
101
103
104
105
17
18
19
103
104
105
91
92
93
21
22
23
95
96
97
21
22
23
99
100
101
21
22
23
107
108
109
127
128
129
107
108
109
131
132
133
107
108
109
135
136
137
111
112
113
127
128
129
111
112
113
131
132
133
111
112
113
135
136
137
115
116
117
127
128
129
115
116
117
131
132
133
115
116
117
135
136
137
119
120
121
127
128
129
119
120
121
131
132
133
119
120
121
135
136
137
123
124
125
127
128
129
123
124
125
131
132
133
123
124
125
135
136
137
139
140
141
155
156
157
139
140
141
159
160
161
143
144
145
155
156
157
143
144
145
159
160
161
147
148
149
155
156
157
147
148
149
159
160
161
151
152
153
155
156
157
151
152
153
159
160
161
in each case independently, optionally with not more than three or two, preferably no more than one, amino acid substitution(s), insertion(s) or deletion(s) compared to these sequences.

### Claim 36 (depends on 29)

The antigen recognizing construct according to claim 29, wherein the construct is a TCR, or a fragment thereof, further comprising a TCR constant region preferably a human or mouse TCR constant region.

### Claim 37

A nucleic acid encoding for an antigen recognizing construct comprising at least one complementary determining region which specifically recognizes a mutated Ras antigen derived spliced peptide variant which comprises a sequence according to SEQ ID NO: 76 to 78, or 163.

### Claim 38 (depends on 37)

A vector comprising a nucleic acid according to claim 37.

### Claim 39 (depends on 29)

A host cell comprising an antigen recognizing construct according to claim 29.

### Claim 40 (depends on 29)

A pharmaceutical composition comprising the antigen recognizing construct according to claim 29, and a pharmaceutical acceptable carrier, stabilizer and/or excipient.

### Claim 41

A method for the treatment of a proliferative disease in a subject, comprising a step of administering to the subject an antigen recognizing construct, wherein the disease comprises a malignant or benign tumor disease, preferably a tumor disease which is positive for the RasG12V mutation, and wherein the antigen recognizing construct comprising at least one complementary determining region which specifically recognizes a mutated Ras antigen derived spliced peptide variant which comprises a sequence according to SEQ ID NO: 76 to 78, or 163.

### Claim 42 (depends on 41)

The method of claim 41, wherein the treatment is an immune therapy, optionally, comprising an adoptive cell transfer, wherein the immune therapy comprises adoptive autologous or heterologous T-cell therapy.

### Claim 43 (depends on 29)

A method of manufacturing a TSA specific antigen recognizing construct expressing cell line, comprising
a. providing a suitable host cell,
b. providing a genetic construct comprising a coding sequence encoding the antigen recognizing construct according to of claim 29,
c. introducing into said suitable host cell said genetic construct, and
d. expressing said genetic construct by said suitable host cell.

### Claim 44

An immunogenic peptide that is selected from the group of peptides comprising at least on sequence according to any of SEQ ID No. 76 to 78, or 163, or a variant thereof.

### Claim 45 (depends on 44)

The immunogenic peptide according to claim 44, wherein the peptide consists essentially of an amino acid sequence according to any of SEQ ID No. 76 to 78, or 163, or a variant thereof.

### Claim 46 (depends on 44)

The immunogenic peptide according to claim 44, wherein said peptide exhibits an overall length of between 9 and 100, preferably between 9 and 30 amino acids.

### Claim 47 (depends on 44)

The immunogenic peptide according to claim 44, consisting of an amino acid sequence according to any of SEQ ID No. 76 to 78, or SEQ ID No. 163.

### Claim 48 (depends on 44)

The immunogenic peptide according to claim 44, having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I, in particular to HLA-A*02.

### Claim 49

A nucleic acid, encoding a peptide selected from the group of peptides comprising at least on sequence according to any of SEQ ID No. 76 to 78, or 163, or a variant thereof.

### Claim 50 (depends on 49)

A host cell comprising a nucleic acid according to claim 49.

### Claim 51

A pharmaceutical composition comprising an immunogenic peptide selected from the group of peptides comprising at least on sequence according to any of SEQ ID No. 76 to 78, or 163, or a variant thereof, and a pharmaceutically acceptable carrier.

### Claim 52

A T-cell receptor (TCR) which recognizes a cell which aberrantly expresses a mutated Ras antigen, the TCR being obtainable from the cytotoxic T lymphocyte (CTL) reactive to an immunogenic peptide comprising at least on sequence according to any of SEQ ID No. 76 to 78, or 163, or a variant thereof.
